| Literature DB >> 32153414 |
Min Wu1, Longtao Liu2, Yanwei Xing1, Shengjie Yang1, Hao Li3, Yu Cao3.
Abstract
Cardiovascular disease (CVD), especially atherosclerosis, is a leading cause of morbidity and mortality globally; it causes a considerable burden on families and caregivers and results in significant financial costs being incurred. Hawthorn has an extensive history of medical use in many countries. In China, the use of hawthorn for the treatment of CVD dates to 659 AD. In addition, according to the theory of traditional Chinese medicine, it acts on tonifying the spleen to promote digestion and activate blood circulation to dissipate blood stasis. This review revealed that the hawthorn extracts possess serum lipid-lowering, anti-oxidative, and cardiovascular protective properties, thus gaining popularity, especially for its anti-atherosclerotic effects. We summarize the four principal mechanisms, including blood lipid-lowering, anti-oxidative, anti-inflammatory, and vascular endothelial protection, thus providing a theoretical basis for further utilization of hawthorn.Entities:
Keywords: Crataegus; atherosclerosis; endothelial dysfunction; hawthorn; inflammation; oxidative stress
Year: 2020 PMID: 32153414 PMCID: PMC7047282 DOI: 10.3389/fphar.2020.00118
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1Crataegus pinnatifida tree and fruits (left). Traditional Chinese herb Shanzha (Fructus Crataegus, prepared pieces of Crataegus pinnatifida var. major) fruit pieces (right).
Figure 2Chemical structures of representative flavonoids in Crataegus pinnatifida.
Figure 4Chemical structures of other compounds in Crataegus pinnatifida.
Major effects and targets of Crataegus in atherosclerosis.
| Effects | Species | Materials | Subjects | Targets | Reference |
|---|---|---|---|---|---|
| Lipid-lowering effect |
| Freeze-dried fruit powder | ApoE-/- mice | ACAT |
|
| SREBP-1c | |||||
| HMG-CoAR, CYP7α | |||||
| FAS | |||||
| PPARα, CPT-1 | |||||
| Fruit powder | New Zealand rabbits | HMG-CoAR, CYP7α |
| ||
| Ethanol extracts | Syrian golden hamsters | HMG-CoAR |
| ||
| ACAT | |||||
| Total flavonoids | 3T3-L1 cells | Leptin |
| ||
|
| 50% ethanol extracts of leaf | Macrophage of ApoE-/- mice | PPARγ, ABCA1, CD36 |
| |
| Antioxidant effect |
| Freeze-dried fruit powder | ApoE-/- mice | SOD1, SOD2, Gpx3 |
|
|
| Aqueous extracts of fruits | Wistar rats | SOD, MDA |
| |
| Endothelial protection |
| Aqueous extracts | Wistar rats | NO, ET |
|
| 6-keto-PGF1α, TXB2 | |||||
|
| WS® 1442 | Rat aorta and human internal mammary artery | Serine 1177 residual of eNOS |
| |
| HUVECs, C57 mice | cAMP/Epac1/Rap1 pathway Ca2+/PKC/RhoA signaling pathway |
| |||
| HUVECs | IP3 Sarcoplasmic/endoplasmic reticulum Ca2+ ATPase |
| |||
| Anti-inflammatory effect |
| 50% ethanol extracts of leaf | Carotid artery atherosclerosis patients | CRP |
|
| Aqueous extracts of fruits | Wistar rats | IL-18 |
| ||
| CRP, IL-1β, IL-8 | |||||
|
| Hawthorn vinegar | Cardiovascular risk patients | CRP |
| |
|
| Methanol extracts | RAW 264.7 cell | TNF-α, IL-1β, IL-6 |
| |
|
| 50% ethanol extracts of leaf | ApoE-/- mice | CRP, NF-κB |
| |
| Anti-apoptotic effect |
| 50% ethanol extracts | ApoE-/- mice | BAX, Bcl-2 |
|
|
| Heartcare™ tablets | Wistar rats | Akt and HIF-1 signaling pathways |
|
6-keto-PGF1α, 6-keto-prostaglandin F1α; ABCA1, ATP-binding cassette transporter 1; ACAT, acyl-CoA cholesterol acyltransferase; Bcl-2, B-cell lymphoma 2; BAX, BCL2-associated X protein; CPT-1, carnitine palmitoyltransterase-1; CRP, C-reactive protein; ET, endothelin; Gpx3, glutathione peroxidase 3; HIF-1, hypoxia-inducible factor 1; HUVECs, human umbilical vein endothelial cells; MDA, malondialdehyde; NF-κB, nuclear factor κB; NO, nitric oxide; PPAR, peroxisome proliferator-activated receptor; SOD, superoxide dismutase; TNF-α, tumor necrosis factor α; TXB2, thromboxane B2.
Figure 5Mechanisms of the protective role of hawthorn in the treatment of atherosclerosis.